| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 396.45% | HC Wainwright & Co. | → $7 | Reiterates | Buy → Buy |
| 07/25/2023 | 325.53% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight |
| 07/24/2023 | 396.45% | HC Wainwright & Co. | $7 → $7 | Reiterates | Buy → Buy |
| 05/12/2023 | 396.45% | HC Wainwright & Co. | → $7 | Reiterates | Buy → Buy |
| 04/26/2023 | 396.45% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 03/10/2023 | 396.45% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 11/02/2022 | 254.61% | Baird | → $5 | Initiates Coverage On | → Outperform |
| 06/14/2022 | 183.69% | B. Riley Securities | → $4 | Initiates Coverage On | → Buy |
| 08/19/2021 | 467.38% | Noble Capital Markets | → $8 | Initiates Coverage On | → Outperform |
| 03/31/2021 | 325.53% | Cantor Fitzgerald | → $6 | Initiates Coverage On | → Overweight |
| 09/17/2020 | — | Noble Capital Markets | Initiates Coverage On | → Outperform |
What is the target price for Lineage Cell Therapeutics (LCTX)?
The latest price target for Lineage Cell Therapeutics (AMEX: LCTX) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $7.00 expecting LCTX to rise to within 12 months (a possible 396.45% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lineage Cell Therapeutics (LCTX)?
The latest analyst rating for Lineage Cell Therapeutics (AMEX: LCTX) was provided by HC Wainwright & Co., and Lineage Cell Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Lineage Cell Therapeutics (LCTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lineage Cell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lineage Cell Therapeutics was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
Is the Analyst Rating Lineage Cell Therapeutics (LCTX) correct?
While ratings are subjective and will change, the latest Lineage Cell Therapeutics (LCTX) rating was a reiterated with a price target of $0.00 to $7.00. The current price Lineage Cell Therapeutics (LCTX) is trading at is $1.41, which is within the analyst's predicted range.